IKENA Oncology (IKENA; Boston, MA, USA) announced that an investigator-initiated trial of IK-007 (AskAt’s EP4 antagonist AAT-007) in metastatic inflammatory breast cancer was launched in September 2021, led by Naoto Ueno, M.D., of the University of Texas MD Anderson Cancer Center. The company made this announcement in its Third Quarter 2021 financial results and corporate update. For further details, please see the company’s press release.
